https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-20 / Cancers (Basel) 2021 May;13(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-20 / Cancers (Basel) 2021 May;13(10)2021-05-20 00:00:002021-05-20 00:00:00Recent Progress in Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-19 / Vaccines (Basel) 2021 May;9(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-19 / Vaccines (Basel) 2021 May;9(5)2021-05-19 00:00:002021-05-19 00:00:00Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-19 / Mol Ther Oncolytics 2021 Sep;22:64-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-19 / Mol Ther Oncolytics 2021 Sep;22:64-712021-05-19 00:00:002021-05-19 00:00:00CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-14 / Ther Apher Dial 2021 Aug;25(4):415-424
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-14 / Ther Apher Dial 2021 Aug;25(4):415-4242021-05-14 00:00:002023-01-31 12:56:12Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-12 / Cancer Med 2021 Jul;10(13):4302-4311
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-12 / Cancer Med 2021 Jul;10(13):4302-43112021-05-12 00:00:002021-08-09 09:14:27Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-12 / Virol J 2021 May;18(1):98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-12 / Virol J 2021 May;18(1):982021-05-12 00:00:002021-05-12 00:00:00A bibliometric review of oncolytic virus research as a novel approach for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-10 / Front Oncol 2021;11:672508
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-10 / Front Oncol 2021;11:6725082021-05-10 00:00:002021-05-10 00:00:00Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-04-21 / Oncol Lett 2021 Jun;21(6):482
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-04-21 / Oncol Lett 2021 Jun;21(6):4822021-04-21 00:00:002023-01-31 13:10:15MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-04-12 / Front Oncol 2021;11:660712
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-04-12 / Front Oncol 2021;11:6607122021-04-12 00:00:002021-04-12 00:00:00Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-04-09 / Phytother Res 2021 Sep;35(9):4913-4929
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-04-09 / Phytother Res 2021 Sep;35(9):4913-49292021-04-09 00:00:002021-12-15 16:20:59Curcumin and cancer biology: Focusing regulatory effects in different signalling pathways
